Gerald Levine, MD
Endocrinology, Diabetes & Metabolism · Santa Monica, CANPI 1508886144
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,850 of the $63,508 with a category attached, or 72.2%. AbbVie accounts for 91.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $45,062 and has fallen 98.3% since, to $788 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $237.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$58K
- Lilly USA, LLC$997
- Clarus Therapeutics Inc.$750
- Novo Nordisk$587
- AstraZeneca$437
- Abbott$427
- plus $2K from 18 others
What the payments were for
- Consulting fees$6001%
- Speaking & faculty fees$45,85072%
- Travel & lodging$9,96516%
- Food & beverage$7,02711%
- Education$60%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 107 | $58,343 |
| Lilly USA, LLC | 40 | $997 |
| Clarus Therapeutics Inc. | 1 | $750 |
| Novo Nordisk | 22 | $587 |
| AstraZeneca | 10 | $437 |
| Abbott | 14 | $427 |
| Ascendis Pharma Endocrinology Inc | 5 | $339 |
| Boehringer Ingelheim | 8 | $338 |
| Mannkind Corporation | 10 | $234 |
| IBSA Pharma Inc. | 10 | $192 |
| Bayer | 5 | $133 |
| Antares Pharma, Inc. | 6 | $128 |
| Sanofi-aventis U.S. LLC | 8 | $123 |
| Vistapharm, Inc. | 5 | $100 |
| Dexcom, Inc. | 3 | $79 |
| Tolmar, Inc. | 3 | $62 |
| Amgen | 2 | $54 |
| Merck | 2 | $36 |
| Corcept Therapeutics | 1 | $35 |
| Johnson & Johnson | 1 | $28 |
| Medtronic | 1 | $24 |
| Halozyme Inc | 1 | $24 |
| Novartis | 1 | $21 |
| Gilead | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,508 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 129 | $153,474 |
| JanumetSitagliptin Phos/Metformin Hcl | 49 | $69,736 |
| TradjentaLinagliptin | 57 | $55,473 |
| SynthroidLevothyroxine Sodium | 536 | $47,322 |
| OzempicSemaglutide | 40 | $37,692 |
| MounjaroTirzepatide | 27 | $34,905 |
| JanuviaSitagliptin Phosphate | 32 | $32,610 |
| XyostedTestosterone Enanthate | 27 | $16,136 |
| TirosintLevothyroxine Sodium | 59 | $15,142 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $14,893 |
| Cinacalcet Hcl | 41 | $13,271 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $7,344 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 18 | $6,573 |
| Testosterone | 54 | $5,633 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $4,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $338 | $208,947186 claims |
| MerckJanumet, Januvia, Janumet Xr | $36 | $117,23993 claims |
| AbbVieSynthroid | $58,343 | $47,322536 claims |
| Novo NordiskOzempic | $587 | $37,69240 claims |
| Lilly USA, LLCMounjaro | $997 | $34,90527 claims |
| Antares Pharma, Inc.Xyosted | $128 | $16,13627 claims |
| IBSA Pharma Inc.Tirosint | $192 | $15,14259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Santa Monica
- Evan AbelSanta Monica$62K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.